Roger Perlmutter holds 2.89M shares of Eikon Therapeutics (NASDAQ: EIKN)

Rhea-AI Filing Summary

Eikon Therapeutics, Inc. disclosure: Roger M. Perlmutter reports beneficial ownership of 2,893,171 shares of Common Stock, representing 5.2% of the class based on 54,138,555 shares outstanding as of March 17, 2026. The position combines 1,190,999 shares held directly, 1,417,315 options exercisable within 60 days of March 31, 2026, and 284,857 shares held by Perlmutter Consulting, Inc.

The filing attributes sole voting and dispositive power over the reported shares to Dr. Perlmutter. The statement is a standard beneficial‑ownership disclosure under Schedule 13G and does not state any transactions or changes in proceeds.

Insights

Corporate Governance Analyst

Significant passive stake disclosure by a senior scientific executive.

Roger M. Perlmutter is reported as beneficial owner of 2,893,171 shares, equal to 5.2% of common stock as of March 17, 2026. The holding combines direct shares, options exercisable within 60 days of March 31, 2026, and shares held by an entity he controls.

The filing is a factual ownership snapshot; governance implications depend on whether the stake is passive or active, which the excerpt does not declare. Subsequent filings would be needed to show any voting intentions or changes.

Equity Compensation Specialist

Options near exercise window materially affect reported beneficial ownership.

The position includes 1,417,315 options exercisable within 60 days of March 31, 2026, which are counted in the beneficial‑ownership total. That treatment follows standard rule‑based inclusion when options are exercisable within the near term.

Whether options are exercised or withheld is not stated here; conversion outcomes and any subsequent dispositions would appear in separate filings if and when they occur.

Key Figures

Beneficial ownership: 2,893,171 shares Percent of class: 5.2% Direct shares held: 1,190,999 shares +3 more

6 metrics

Beneficial ownership 2,893,171 shares reported on Schedule 13G

Percent of class 5.2% based on 54,138,555 shares outstanding as of March 17, 2026

Direct shares held 1,190,999 shares directly held by Dr. Perlmutter

Options exercisable 1,417,315 options exercisable within 60 days of March 31, 2026

Entity holdings 284,857 shares held by Perlmutter Consulting, Inc.

Shares outstanding used 54,138,555 shares as of March 17, 2026 per issuer 10‑K

Key Terms

beneficially owned, sole dispositive power, options exercisable within 60 days, Schedule 13G

4 terms

beneficially owned regulatory

"Amount beneficially owned: See Row 9 of the cover page."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole Dispositive Power 2,893,171.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

options exercisable within 60 days financial

"options to purchase 1,417,315 shares ... exercisable within 60 days of March 31, 2026"

Schedule 13G regulatory

"This Schedule is filed by Roger M. Perlmutter."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

EIKON THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

282564103

(CUSIP Number)

02/04/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 282564103

1

Names of Reporting Persons

PERLMUTTER ROGER M

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,893,171.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,893,171.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,893,171.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The shares listed in Rows 5 and 7 consist of (i) (a) 1,190,999 shares of common stock, $0.0001 par value per share (the Common Stock) of Eikon Therapeutics, Inc. (the Issuer) and (b) options to purchase 1,417,315 shares of Common Stock, exercisable within 60 days of March 31, 2026, held directly by Dr. Roger M. Perlmutter, and (ii) 284,857 shares of Common Stock held directly by Perlmutter Consulting, Inc. Dr. Perlmutter is the president and sole shareholder of Perlmutter Consulting, Inc. and may be deemed to have sole power to vote and to dispose its shares. The percentage in Row 11 is based on 54,138,555 shares of Common Stock outstanding on March 17, 2026 as reported by the Issuer on its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: EIKON THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 230 HARRIET TUBMAN WAY, MILLBRAE, CALIFORNIA, 94030
Item 2.
(a)	Name of person filing: This Schedule is filed by Roger M. Perlmutter.
(b)	Address or principal business office or, if none, residence: 230 Harriet Tubman Way, Millbrae CA 94030
(c)	Citizenship: See Row 4 of the cover page.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP Number(s): 282564103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of the cover page.
(b)	Percent of class: See Row 11 of the cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of the cover page.
	(ii) Shared power to vote or to direct the vote: See Row 6 of the cover page.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of the cover page.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of the cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PERLMUTTER ROGER M

Signature:	/s/ Roger M. Perlmutter
Name/Title:	Roger M. Perlmutter
Date:	05/13/2026